These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

745 related items for PubMed ID: 16618754

  • 21. Cancer gene therapy using a novel secretable trimeric TRAIL.
    Kim CY, Jeong M, Mushiake H, Kim BM, Kim WB, Ko JP, Kim MH, Kim M, Kim TH, Robbins PD, Billiar TR, Seol DW.
    Gene Ther; 2006 Feb; 13(4):330-8. PubMed ID: 16195699
    [Abstract] [Full Text] [Related]

  • 22. VEGI-armed oncolytic adenovirus inhibits tumor neovascularization and directly induces mitochondria-mediated cancer cell apoptosis.
    Xiao T, Fan JK, Huang HL, Gu JF, Li LY, Liu XY.
    Cell Res; 2010 Mar; 20(3):367-78. PubMed ID: 19918267
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Synergistic antitumor effect of TRAIL and IL-24 with complete eradication of hepatoma in the CTGVT-DG strategy.
    Cai Y, Liu X, Huang W, Zhang K, Liu XY.
    Acta Biochim Biophys Sin (Shanghai); 2012 Jun; 44(6):535-43. PubMed ID: 22635106
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. [Security of dual cancer-specific targeting vector and its cytotoxic effect when harbored].
    Wang J, Gu JF, Yang SY, Xiao T, Qi R, Sun LY, Liu XY.
    Ai Zheng; 2006 Apr; 25(4):385-92. PubMed ID: 16613667
    [Abstract] [Full Text] [Related]

  • 27. Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.
    Liu TC, Wang Y, Hallden G, Brooks G, Francis J, Lemoine NR, Kirn D.
    Gene Ther; 2005 Sep; 12(17):1333-46. PubMed ID: 15920462
    [Abstract] [Full Text] [Related]

  • 28. Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors.
    VanOosten RL, Earel JK, Griffith TS.
    Cancer Gene Ther; 2006 Jun; 13(6):628-32. PubMed ID: 16456549
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Oncolytic adenovirus-mediated shRNA against Apollon inhibits tumor cell growth and enhances antitumor effect of 5-fluorouracil.
    Chu L, Gu J, Sun L, Qian Q, Qian C, Liu X.
    Gene Ther; 2008 Apr; 15(7):484-94. PubMed ID: 18239605
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. A tumor-specific conditionally replicative adenovirus vector expressing TRAIL for gene therapy of hepatocellular carcinoma.
    Ren XW, Liang M, Meng X, Ye X, Ma H, Zhao Y, Guo J, Cai N, Chen HZ, Ye SL, Hu F.
    Cancer Gene Ther; 2006 Feb; 13(2):159-68. PubMed ID: 16082383
    [Abstract] [Full Text] [Related]

  • 33. Reactive oxygen species regulate caspase activation in tumor necrosis factor-related apoptosis-inducing ligand-resistant human colon carcinoma cell lines.
    Izeradjene K, Douglas L, Tillman DM, Delaney AB, Houghton JA.
    Cancer Res; 2005 Aug 15; 65(16):7436-45. PubMed ID: 16103097
    [Abstract] [Full Text] [Related]

  • 34. Differential expression of members of the tumor necrosis factor alpha-related apoptosis-inducing ligand pathway in prostate cancer cells.
    Sridhar S, Ali AA, Liang Y, El Etreby MF, Lewis RW, Kumar MV.
    Cancer Res; 2001 Oct 01; 61(19):7179-83. PubMed ID: 11585752
    [Abstract] [Full Text] [Related]

  • 35. Sodium nitroprusside enhances TRAIL-induced apoptosis via a mitochondria-dependent pathway in human colorectal carcinoma CX-1 cells.
    Lee YJ, Lee KH, Kim HR, Jessup JM, Seol DW, Kim TH, Billiar TR, Song YK.
    Oncogene; 2001 Mar 22; 20(12):1476-85. PubMed ID: 11313891
    [Abstract] [Full Text] [Related]

  • 36. Potent antitumor efficacy of ST13 for colorectal cancer mediated by oncolytic adenovirus via mitochondrial apoptotic cell death.
    Yang M, Cao X, Yu MC, Gu JF, Shen ZH, Ding M, Yu DB, Zheng S, Liu Xy.
    Hum Gene Ther; 2008 Apr 22; 19(4):343-53. PubMed ID: 18355116
    [Abstract] [Full Text] [Related]

  • 37. Prevention of posterior capsule opacification by the induction of therapeutic apoptosis of residual lens cells.
    Malecaze F, Decha A, Serre B, Penary M, Duboue M, Berg D, Levade T, Lubsen NH, Kremer EJ, Couderc B.
    Gene Ther; 2006 Mar 22; 13(5):440-8. PubMed ID: 16251995
    [Abstract] [Full Text] [Related]

  • 38. Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy.
    Bernt KM, Ni S, Tieu AT, Lieber A.
    Cancer Res; 2005 May 15; 65(10):4343-52. PubMed ID: 15899826
    [Abstract] [Full Text] [Related]

  • 39. Double E1B 19 kDa- and E1B 55 kDa-deleted oncolytic adenovirus in combination with radiotherapy elicits an enhanced anti-tumor effect.
    Kim J, Kim PH, Yoo JY, Yoon AR, Choi HJ, Seong J, Kim IW, Kim JH, Yun CO.
    Gene Ther; 2009 Sep 15; 16(9):1111-21. PubMed ID: 19494843
    [Abstract] [Full Text] [Related]

  • 40. Augmenting the antitumor effect of TRAIL by SOCS3 with double-regulated replicating oncolytic adenovirus in hepatocellular carcinoma.
    Wei RC, Cao X, Gui JH, Zhou XM, Zhong D, Yan QL, Huang WD, Qian QJ, Zhao FL, Liu XY.
    Hum Gene Ther; 2011 Sep 15; 22(9):1109-19. PubMed ID: 21361790
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 38.